Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

NCT00239200 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

29

Enrollment

OTHER

Sponsor class

Stopped notification from sponsor

Conditions

Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus

Interventions

DRUG: Lapatinib

Sponsor

University of Michigan Rogel Cancer Center